Apostolos Papandreou,Nivedita Singh,Lorita Gianfrancesco,Dimitri Budinger,Katy Barwick,Alexander Agrotis,Christin Luft,Ying Shao,An-Sofie Lenaerts,Allison Gregory,Suh Young Jeong,Penelope Hogarth,Susan Hayflick,Serena Barral,Janos Kriston-Vizi,Paul Gissen,Manju A. A Kurian,Robin Ketteler

Abstract:Beta-Propeller Protein-Associated Neurodegeneration (BPAN) is one of the commonest forms of Neurodegeneration with Brain Iron Accumulation, caused by mutations in the gene encoding the autophagy-related protein, WDR45. The mechanisms linking autophagy, iron overload and neurodegeneration in BPAN are poorly understood and, as a result, there are currently no disease-modifying treatments for this progressive disorder. We have developed a patient-derived, induced pluripotent stem cell (iPSC)-based midbrain dopaminergic neuronal cell model of BPAN (3 patient, 2 age-matched controls and 2 isogenic control lines) which shows defective autophagy and aberrant gene expression in key neurodegenerative, neurodevelopmental and collagen pathways. A high content imaging-based medium-throughput blinded drug screen using the FDA-approved Prestwick library identified 5 cardiac glycosides that both corrected disease-related defective autophagosome formation and restored BPAN-specific gene expression profiles. Our findings have clear translational potential and emphasise the utility of iPSC-based modelling in elucidating disease pathophysiology and identifying targeted therapeutics for early-onset monogenic disorders.

Cardiac glycosides restore autophagy flux in an iPSC-derived neuronal model of WDR45 deficiency